Introduction
FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth

Materials and methods
Plasmids
The reporter construct ERE-Luc (oestrogen-responsive element-containing luciferase reporter) and expression vectors for ER␣ and ER␤ have been described previously [16] . The (Clontech) were sequentially transformed into AH109 yeast cells as previously described [17] .
Yeast two-hybrid assay
The bait plasmid was generated by inserting PCR-amplified cDNA fragment encoding the AF1 domain (amino acids 1-145) of ER␤ into pGBKT7 (Clontech). The Matchmaker two-hybrid system (Clontech) was used to isolate proteins that interacted with the ER␤ bait protein. The bait plasmid and a human mammary gland cDNA library
GST pull-down assay
The GST alone and GST fusion proteins were expressed in bacteria and purified according to the manufacturer's protocols (Amersham Pharmacia). ER␣ or ER␤ was translated in vitro in the TNT system (Promega, Madison, WI, USA)
. 35 
S-labelled ER␣ or ER␤ was incubated
with GST or GST fusion proteins bound to glutathione-Sepharose beads, and the adsorbed proteins were analysed as previously described [18] . [19] .
Co-immunoprecipitation
Luciferase assay
Cells were seeded in 24- [18] .
SiRNA experiments
The 
Cell growth assays
Anchorage-dependent cell proliferation was analysed by crystal violet assay as described previously [17] . (Fig. 1B) .
Results
Interaction of FHL1 with ER␣ and ER␤ in vitro and in vivo
Since ER␤ shares similarity with ER␣, the possibility that FHL1 interacts with ER␣ was investigated using GST pull-down assay. As shown in Fig. 1C 
FHL1 modulates the transcriptional activity of ER␣ and ER␤b
To determine whether the FHL1-ER␣/ER␤ interaction affects oestrogen-responsive gene transcription, ER␣
Ϫ and ER␤ ϩ MCF7 (Fig. 3C) . Notably, FLAG-tagged FHL1, FHL1 and FHL1 were expressed at comparable levels (Fig. 3C) . (Fig. 3D) . These data strongly suggest that FHL1 acts through ER␣ to decrease ERE-Luc reporter transcription. [21] , two well-studied oestrogen-responsive genes (Fig. 4A) (Fig. 4B) . Similar results were obtained in MCF7 cells (Fig. 4C and D) . (Fig. 6A) , whereas ZR75-1 cells transfected with FHL1 siRNAs grew faster than those with control siRNA (Fig. 6B) (Fig. 6C) .
cells were co-transfected with the oestrogen-responsive reporter, ERE-Luc, and FLAG-tagged FHL1 or FHL1 small interfering RNAs (siRNAs). Both in the presence and absence of E2, FHL1 overexpression decreased ERE-Luc reporter activity (Fig. 2A). With ER␣-specific agonist, PPT, or ER␤-specific agonist, DPN, FHL1 overexpression also inhibited ERE-Luc reporter activity, suggesting that FHL1 regulates both ER␣ and ER␤ transcriptional activity. FHL1 also inhibited ERE-Luc reporter activity in human breast cancer ZR75-1 cells (Fig. 2B). Transient co-expression of FHL1 and ER did not affect the protein levels of ER␣ and ER␤ in MCF7 and ZR75-1 cells (data not shown), so the decrease of the transactivation of ER␣ and ER␤ by FHL1 was not due to a modulation of the protein levels of ER␣ and ER␤. Consistent with the results of FHL1 overexpression, siRNA knockdown of endogenous FHL1 increased ERE-Luc reporter activity (Fig. 2C).
Interaction of FHL1 and ER is required for repression of oestrogen-responsive transcription
To further determine whether ER␣ is required for FHL1-mediated repression of ERE-Luc reporter activity, human breast cancer SKBR3 cells, which lack endogenous ER␣ were used in the ERELuc assay. Co-transfection of FHL1 and the ERE-Luc reporter into SKBR3 cells did not decrease ERE-Luc reporter transcription, whereas co-transfection of these genes with human ER␣ expression vector led to repression of the ERE-Luc
FHL1 decreases the expression of endogenous oestrogen-responsive genes
(B) Mapping of the ER␣ interaction region of FHL1. 293T cells were co-transfected with lac-tagged ER␣ and FLAG-tagged full-length FHL1 or its mutants in the presence of E2. Lysates from the transfected cells were immunoprecipitated with anti-FLAG antibody, and the immunoprecipitates were assayed with anti-lac antibody. Also shown are schematic diagrams of the constructs used in this study. (C) Luciferase assay with ZR75-1 cells co-transfected with 0.2 g of ERE-Luc and 1.0 g of FLAG-tagged FHL1, FHL1(1-228), or FHL1(1-169) as indicated (upper panel). Values are mean Ϯ S.D. of triplicate measurements and have been repeated three times with similar results. Expression of FLAG-tagged FHL1, FHL1(1-228) and FHL1-(1-169) was detected by immunoblotting with anti-FLAG (lower panel
FHL1 regulates binding of ER␣ to oestrogen-responsive promoter
To investigate molecular mechanism by which FHL1 modulates ER transcriptional activity, the effect of FHL1 on ER␣ binding to ERE sequence was determined by gel shift assay. As expected, the biotin-labelled ERE, but not mutant ERE (EREM), bound to proteins from ER ϩ MCF7 nuclear extracts in the absence or presence of E2 (Fig. 5A and data not shown). The binding was specifically inhibited by a 100-fold molar excess of a cold ERE oligonucleotide. The addition of human anti-ER␣ antibody to the reaction caused a supershift, suggesting that ER␣ protein from MCF7 nuclear extracts specifically binds to ERE sequence. Importantly, overexpression of FHL1 abolished the binding of ER␣ to ERE (Fig. 5A). Opposite effects were observed with FHL1 siRNAs. Consistent with the results of the reporter gene transcription assays, the FHL1(1-228) mutant, which is as active as wild-type FHL1 in repression of ER transcriptional activity, also abolished ER␣ binding to ERE. Conversely, the FHL1(1-169) mutant, which increases ER transcriptional activity, enhanced the binding of ER␣ to ERE. To test whether FHL1 affects recruitment of ER␣ to an oestrogen-responsive promoter in vivo, chromatin immunoprecipitation (ChIP) experiments were performed for the pS2 promoter. As shown in Fig. 5B, ER␣ displayed a clear E2-stimulated recruitment to the pS2 promoter, but not a region approximately 2 kb upstream of the pS2 promoter. Consistent with the results of the gel shift assay, FHL1 overexpression decreased recruitment of ER␣ to the pS2 promoter (Fig. 5B). Taken together, these data suggest that FHL1 modulation of ER transcription activity may be through repression of ER␣ binding to the ERE sequence within oestrogen-responsive genes.
FHL1 inhibits breast cancer cell growth
. Similar results were observed in MCF7 cells (data not shown). In addition, in agreement with the results of the transcriptional experiments, the anti-oestrogens 4-OHT and ICI 182,780 further promoted the effect of FHL1 on breast cancer cell growth
We then detected the effect of FHL1 on anchorage-independent breast cancer cell growth. As shown in Fig. 6D 
Fig. 4 FHL1 regulates oestrogen-responsive gene expression. (A) ZR75-1 cells transfected with expression vector of FLAG-tagged FHL1 or FHL1(1-169) were treated with or without 1 nM E2 for 24 hrs. Whole cell lysate was used for western blot analysis of the expression of the FLAGtagged proteins and oestrogen-responsive target genes, pS2 and cathepsin D. The densitometric quantitation of pS2 and cathepsin D bands normalized to GAPDH from a representative experiment is presented as a histogram. (B) ZR75-1 cells transfected with FHL1 siRNAs or control vector were treated as in (A). Whole cell lysate was used for western blot analysis with the indicated antibodies. The densitometric quantitation of FHL1, pS2 and cathepsin D bands normalized to GAPDH from a representative experiment is presented as a histogram. (C and D) MCF7 cells transfected with expression vector of FHL1 (C) or FHL1 siRNAs (D) were treated and analysed as in (B
FHL1 expression in breast cancer patients and its correlation with clinical factors
FHL1 has been shown to be down-regulated in 15 breast cancer patients [22] . We further detected the expression of FHL1 by immunohistochemistry in 46 pairs of human breast tumours and matched non-tumour breast tissues. Similar to the previous Fig. 6 FHL1 inhibits [29] , silencing mediator for retinoid and thyroid hormone receptors (SMRT) [30] , receptorinteracting protein (RIP)140 [31] and breast cancer susceptibility gene (BRCA)1 [32, 33] [35] , activator protein-1 (AP-1) [36] , cyclic-AMP response element binding protein (CREB) [37] , promyelocytic leukaemia zinc finger protein (PLZF) [38] , serum response factor (SRF) [39] and Forkhead box class O protein 1 (FOXO1) [40] . Notably, FHL2 has been shown to interact with the AF1 domain of ER␣, but have no effect on ER␣-dependent transcriptional activity in African green monkey kidney COS-1 cells [41] 
